In the past two years, a spate of technological advances and promising results in mice have been laying the groundwork for ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the smaller biotech ...